Abstract
AbstractPecFent is a new intranasal formulation of fentanyl licensed for the management of breakthrough pain in cancer patients receiving opioid therapy. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects and Drs Monica Chogle and William Campbell comment on its place in breakthrough pain management. Copyright © 2011 Wiley Interface Ltd
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
